Data show that STC-15 is effective as a single agent and in combination with VENCLEXTA
Storm Therapeutics, a company focused on ribonucleic acid modifying enzymes (RMEs) for oncology, has presented new data on its candidate METTL3 inhibitor, STC-15.
New data on acute myeloid leukemia (AML) preclinical models were presented at the American Association for Cancer Research (AACR) Special Meeting – Acute Myeloid Leukemia and Myelodysplastic Syndromes.
This presentation detailed studies of METTL3 as monotherapy or in combination with venetoclax in in vitro and in vivo AML models.
On the other hand, studies showed that STC-15 inhibited the proliferation of several AML cell lines, inhibited the proliferation of AML samples from 12 patients, and reduced protein levels in the majority of AML cell lines in a dose-dependent manner. , demonstrated synergistic inhibition of tumor cell growth when combined with venetoclax.
Storm CEO and President Jerry McMahon explains:
He added: “The ongoing phase 1 repeated escalating dose trial in solid tumors is focused on establishing his STC-15 potential doses and regimens to conduct future clinical trials in AML and solid tumors. .”
Storm Chief Scientific Officer Oliver Rausch added: Further validating our previous publication that treatment with a METTL3 inhibitor resulted in downregulation of BCL2 protein levels in several AML cell lines and in vivo models, providing a rationale for conducting clinical trials in AML with STC We are delighted with the data results. -15.”
STC-15 is progressing to ongoing Phase 1 trials.
